The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study

BackgroundPD-1/L1 inhibitor-based immunotherapy is currently under investigation in biliary tract cancer (BTC). Apatinib combined with camrelizumab has achieved promising results in various tumor types. The aim of this study was to assess the safety and efficacy of apatinib plus camrelizumab for adv...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Dongxu Wang, Xu Yang, Junyu Long, Jianzhen Lin, Jinzhu Mao, Fucun Xie, Yunchao Wang, Yanyu Wang, Ziyu Xun, Yi Bai, Xiaobo Yang, Mei Guan, Jie Pan, Samuel Seery, Xinting Sang, Haitao Zhao
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2021-04-01
Edice:	Frontiers in Oncology
Témata:	apatinib camrelizumab (SHR-1210) advanced biliary tract cancer combination therapy PD-1/L1 blockade target therapy
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2021.646979/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!